Arrowstreet Capital Limited Partnership Boosts Stock Holdings in Stryker Corporation $SYK

Arrowstreet Capital Limited Partnership grew its holdings in Stryker Corporation (NYSE:SYK) by 241.9% in the 1st quarter, HoldingsChannel reports. The firm owned 1,555,638 shares of the medical technology company’s stock after buying an additional 1,100,673 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Stryker were worth $511,167,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after acquiring an additional 133,892 shares in the last quarter. State Street Corp grew its stake in Stryker by 2.1% in the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after purchasing an additional 311,507 shares during the last quarter. Geode Capital Management LLC raised its holdings in Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Stryker during the fourth quarter worth $1,822,272,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK opened at $319.15 on Friday. The company has a 50 day simple moving average of $314.21 and a two-hundred day simple moving average of $335.70. The stock has a market cap of $122.35 billion, a price-to-earnings ratio of 36.94, a PEG ratio of 1.98 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.14.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the previous year, the company earned $2.84 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts predict that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 323,264 shares of company stock worth $100,659,489 over the last quarter. 4.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SYK. BTIG Research set a $371.00 price objective on Stryker in a research report on Monday, July 13th. Barclays reduced their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Needham & Company LLC lowered their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Canaccord Genuity Group dropped their price target on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.